Samsung Biologics Unveils Organoid Platform to Boost Drug Discovery

• Samsung Biologics launches organoid-based drug screening for precision medicine.
• Organoids mimic human organs to predict drug efficacy and patient response.
• New service expands capabilities from target discovery to clinical planning

The launch of Samsung Organoids, which is a advanced drug screening services to support clients in drug discovery and development was announced by Samsung Biologics, a leading contract development and manufacturing organization ( CDMO)

Organoids are three-dimensional cell culture systems designed to closely replicate human organs, providing clinically relevant insights that enhance the understanding of specific drug responses and improve lead selection. These organoids are gaining recognition as a novel research model because of their high resemblance to living tissues and their potential uses in biomarker discovery and drug efficacy prediction. Samsung Organoids facilitate precision screening to anticipate patient responses, optimize preclinical development, and expedite the process toward investigational new drug (IND) filings by utilizing data-driven analysis of candidate molecules. With the introduction of this initiative, Samsung Biologics broadens its operations to encompass preclinical research, offering services that cover target discovery, lead selection, preclinical development, and clinical trial planning. Utilizing its proficiency in development and manufacturing, the company will deliver data-driven, multi-modal insights regarding the properties and mechanisms of candidate molecules.  By assisting clients in overcoming challenges that may occur during the drug discovery process, Samsung Biologics seeks to improve clinical success rates.

Also Read: Enzene Introduces New Drug Discovery Division

“The latest service launch reflects our unwavering commitment to driving innovation by improving drug success rates and creating new possibilities in personalized medicine,” said John Rim, CEO and president of Samsung Biologics. “The addition of research services is a significant move for us to create added value for clients by supporting the drug life cycle from start to finish with thorough therapeutic analysis.”